Mesothelioma is not inherited in the traditional sense, but a genetic predisposition to developing it can be. At least 80% of mesothelioma cases are linked to asbestos exposure, making it overwhelmingly an environmental disease. Yet only about 5% of people with long-term, intense asbestos exposure ever develop mesothelioma, which points to genetic factors that make certain individuals more vulnerable than others.
The distinction matters: you don’t inherit mesothelioma itself, but you can inherit gene mutations that significantly raise your risk, especially if you’re also exposed to asbestos. And families that seem to share a genetic pattern of mesothelioma sometimes turn out to share something else entirely: the same household asbestos exposure.
The BAP1 Gene and Inherited Risk
The most well-established genetic link to mesothelioma involves the BAP1 gene. When this gene works normally, it acts as a tumor suppressor, helping cells repair damaged DNA. When someone inherits a mutated copy, their cells lose some of that protective function, and the risk of several cancers rises. This is known as BAP1 tumor predisposition syndrome.
BAP1 mutations follow an autosomal dominant inheritance pattern. That means only one copy of the altered gene, from one parent, is enough to increase cancer risk. If a parent carries the mutation, each child has a 50% chance of inheriting it. People with this syndrome face elevated risk for mesothelioma, a specific type of eye cancer called uveal melanoma, clear cell kidney cancer, certain skin cancers, and unusual skin growths called atypical Spitz tumors. Cancers that develop in people with BAP1 mutations tend to appear at younger ages and behave more aggressively than typical cases.
One striking finding about BAP1 carriers who do develop mesothelioma: they tend to live significantly longer than patients without the mutation. Research published in the journal Carcinogenesis found that mesothelioma patients with germline BAP1 mutations had a median survival of 5 years, compared with less than 1 year for the general mesothelioma population tracked by the U.S. SEER cancer database. Their five-year survival rate was 47%, versus just 6.7% for typical cases. That translates to roughly a sevenfold improvement in long-term survival. The reasons aren’t fully understood, but the tumors that develop in BAP1 carriers may have distinct biological characteristics that respond differently to treatment.
Other Genes That May Play a Role
BAP1 gets the most attention, but it isn’t the only gene involved. Genomic studies of mesothelioma tumors have identified alterations in several other genes at meaningful rates. Changes in CDKN2A, CDKN2B, NF2, TP53, and SETD2 each appear in at least 10% of mesothelioma tumors. Many of these genes are involved in DNA repair or controlling cell growth. When they malfunction, cells become less capable of fixing the kind of damage that asbestos fibers cause.
Some of these mutations are somatic, meaning they develop during a person’s lifetime rather than being inherited. But germline (inherited) mutations in DNA repair genes like BRCA2 and CHEK2 have also been detected in mesothelioma patients. The NIH currently enrolls mesothelioma patients and their family members for long-term follow-up if they carry germline mutations in BAP1 or other cancer predisposition genes, reflecting growing recognition that inherited variants beyond BAP1 may matter.
How Genes and Asbestos Work Together
The interaction between genetics and asbestos exposure is central to understanding mesothelioma risk. Asbestos fibers are too long for the body’s immune cells to fully engulf. This “frustrated” cleanup process causes immune cells to release highly reactive molecules that damage DNA in surrounding tissue. Over years and decades, this damage accumulates.
In most people, DNA repair systems catch and fix these errors before they lead to cancer. But in someone who inherited a faulty copy of BAP1 or another repair gene, the correction process is compromised. Damaged cells survive and multiply instead of being eliminated. When those cells also develop mechanisms to avoid the body’s normal defenses against abnormal growth, cancer can take hold. This is why asbestos exposure and genetic susceptibility aren’t competing explanations. They’re collaborators. A person with a BAP1 mutation who is never exposed to asbestos may never develop mesothelioma. A person exposed to asbestos who has fully functional tumor suppressor genes has a better chance of their body handling the damage. The combination of both factors is what dramatically raises risk.
When Family Clusters Aren’t Genetic
Families sometimes see multiple members diagnosed with mesothelioma, and the natural assumption is that the disease must be genetic. Often, the real explanation is shared asbestos exposure within the household. This is called para-occupational exposure: a worker brings asbestos fibers home on their clothes, hair, or skin, and family members inhale them during routine activities like doing laundry or hugging.
This pathway is well documented and surprisingly potent. A meta-analysis of multiple studies found that household contacts of asbestos workers had five times the typical risk of developing mesothelioma. One study of nearly 1,800 women married to asbestos cement plant workers found mesothelioma rates more than 25 times higher than expected. Lung tissue analysis in women exposed this way showed asbestos fiber levels comparable to those in men with moderate occupational exposure, such as construction workers. The risk was similar whether the family member’s main contact was living with the worker or specifically handling their work clothes.
Over the past few decades, hundreds of mesothelioma cases have been reported among family members of asbestos workers across multiple countries. These clusters can look hereditary on the surface, since the disease appears in parents and children or among siblings. Distinguishing true genetic predisposition from shared environmental exposure requires genetic testing and a careful exposure history.
Genetic Testing and Screening
Genetic testing is available for BAP1 and other cancer predisposition genes. Current NIH protocols consider testing appropriate for mesothelioma patients themselves, first-degree relatives of someone with mesothelioma, and relatives of confirmed BAP1 mutation carriers. For BAP1 and TP53 mutations, testing can be offered from age 2. For other relevant mutations, testing is generally offered from age 16.
If a BAP1 mutation is identified, the question becomes what to do about it. Surveillance recommendations exist but remain based primarily on expert opinion rather than large-scale evidence, since the syndrome is rare. American and Australian groups have published screening guidelines, though recommendations vary. The challenge with any rare cancer predisposition syndrome is finding the right balance: enough monitoring to catch cancers early, without so many tests that they lead to unnecessary biopsies and anxiety. Screening typically focuses on the organs most commonly affected, including the skin, eyes, kidneys, and the lining of the chest and abdomen.
For families with a known BAP1 mutation, predictive testing for at-risk relatives is generally considered appropriate starting in late adolescence, when surveillance protocols would begin. Even when a genetic variant’s significance is uncertain, doctors may recommend skin and eye screening for close relatives while further evaluation is ongoing.